Targeting estrogen receptor mutations for treatment of endocrine therapy resistance in breast cancer

被引：0
|
作者：
Alluri, P. G. [1 ]
Larios, J. M. [1 ]
Malik, R. [1 ]
Hayes, D. F. [1 ]
Speers, C. W. [1 ]
Rae, J. M. [1 ]
Chinnaiyan, A. M. [1 ]
机构：
[1] Univ Michigan, Sch Med, Ann Arbor, MI USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-12-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-12-05
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
    Reinert, Tomas
    Ramalho, Susana
    Antunes de Vasconcelos, Vivian Castro
    Silva, Leonardo Roberto
    Ribeiro da Silva, Ana Elisa
    de Andrade, Camila Annicchino
    de Paula Leite Kraft, Maria Beatriz
    Coelho, Guilherme Portela
    Mandelli, Jovana
    Binotto, Monique
    Cabello, Cesar
    de Paiva Silva, Geisilene Russano
    Bines, Jose
    Barrios, Carlos H.
    Ellis, Matthew J.
    Graudenz, Marcia Silveira
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [42] Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy
    Poterala, Johanna E.
    Wisinski, Kari B.
    CANCER, 2022, 128 (09) : 1724 - 1726
  • [43] Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells
    Kettner, Nicole M.
    Bui, Tuyen
    Chen, Xian
    Hunt, Kelly K.
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
    Inda, Marcia A.
    Blok, Erik J.
    Kuppen, Peter J. K.
    Charehbili, Ayoub
    den Biezen-Timmermans, Eveline C.
    van Brussel, Anne
    Fruytier, Sevgi E.
    Kranenbarg, Elma Meershoek-Klein
    Kloet, Susan
    van der Burg, Bart
    Martens, John W. M.
    Sims, Andrew H.
    Turnbull, Arran K.
    Dixon, J. Michael
    Verhaegh, Wim
    Kroep, Judith R.
    van de Velde, Cornelis J. H.
    van de Stolpe, Anja
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (02) : 680 - 689
  • [45] Subsequent endocrine therapy after becoming to resistance of 'estrogen therapy' is beneficial as a salvage treatment for the late stage metastatic breast cancer
    Iwase, H.
    Yamamoto, Y.
    Yamamoto-Ibusuki, M.
    Murakami, K-I
    Inao, T.
    Okumura, Y.
    Omoto, Y.
    CANCER RESEARCH, 2013, 73
  • [46] Estrogen receptor downregulators: New options in endocrine therapy for advanced breast cancer - Introduction
    O'Shaughnessy, J
    Bhardwaj, S
    CLINICAL THERAPEUTICS, 2002, 24 : A1 - A2
  • [47] Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
    Neupane, Niraj
    Bawek, Sawyer
    Gurusinghe, Sayuri
    Ghaffary, Elham Moases
    Mirmosayyeb, Omid
    Thapa, Sangharsha
    Falkson, Carla
    O'Regan, Ruth
    Dhakal, Ajay
    CANCERS, 2024, 16 (03)
  • [48] Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
    Kuukasjarvi, T
    Kononen, J
    Helin, H
    Holli, K
    Isola, J
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) : 2584 - 2589
  • [49] Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-a breast cancer risk
    Arnone, Alana A.
    Tsai, Yu-Ting
    Cline, J. Mark
    Wilson, Adam S.
    Westwood, Brian
    Seger, Meghan E.
    Chiba, Akiko
    Howard-McNatt, Marissa
    Levine, Edward A.
    Thomas, Alexandra
    Soto-Pantoja, David R.
    Cook, Katherine L.
    CELL REPORTS MEDICINE, 2025, 6 (01)
  • [50] Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
    McDonnell, Donald P.
    Wardell, Suzanne E.
    Norris, John D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (12) : 4883 - 4887
12345